68003-38-3
基本信息
2-(4-氯-3-硝基苯基磺酰胺基)苯甲酸
SLC25A1 inhibitor CTPI-2
2-(4'-Chloro-3'-nitrobenzenesulfonamido)benzoic acid
2-[(4-chloro-3-nitrophenyl)sulphonyl]anthranilic acid
Benzoic acid, 2-(((4-chloro-3-nitrophenyl)sulfonyl)amino)-
2-(4-Chloro-3-nitrophenylsulfonylamino)benzenecarboxylic acid
macrophage,carrier,CTPI-2,NSCLC,transporter,glucose,steatohepatitis,CTPI 2,Mitochondrial Metabolism,steatosis,inflammatory,inhibit,citrate,Inhibitor,mitochondrial,CTPI2
物理化学性质
| 沸点 | 564.8±60.0 °C(Predicted) |
| 密度 | 1.660±0.06 g/cm3(Predicted) |
| 储存条件 | -20°C储存 |
| 溶解度 | DMSO:125 mg/mL(350.40 mM) |
| 酸度系数(pKa) | 3.19±0.36(Predicted) |
| 形态 | 固体 |
| 颜色 | Off-white to light yellow |
| InChI | 1S/C13H9ClN2O6S/c14-10-6-5-8(7-12(10)16(19)20)23(21,22)15-11-4-2-1-3-9(11)13(17)18/h1-7,15H,(H,17,18) |
| InChIKey | NJTHPOSQGFJTDP-UHFFFAOYSA-N |
| SMILES | [S](=O)(=O)(Nc2c(cccc2)C(=O)O)c1cc(c(cc1)Cl)[N+](=O)[O-] |
| EPA化学物质信息 | Benzoic acid, 2-[[(4-chloro-3-nitrophenyl)sulfonyl]amino]- (68003-38-3) |
安全数据
| 危险性符号(GHS) | ![]() GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H312-H315-H319-H332-H335 |
| 防范说明 | P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501 |
| WGK Germany | WGK 3 |
| TSCA | TSCA listed |
| 存储类别 | 11 - Combustible Solids |
2-(4-氯-3-硝基苯基磺酰胺基)苯甲酸价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-123986 | 2-(4-氯-3-硝基苯基磺酰胺基)苯甲酸 CTPI-2 | 68003-38-3 | 25 mg | 415元 |
| 2026/09/15 | HY-123986 | 2-(4-氯-3-硝基苯基磺酰胺基)苯甲酸 CTPI-2 | 68003-38-3 | 10 mM * 1 mL in DMSO | 456元 |
| 2026/09/15 | HY-123986 | 2-(4-氯-3-硝基苯基磺酰胺基)苯甲酸 CTPI-2 | 68003-38-3 | 50 mg | 584元 |
常见问题列表
| Target | Value |
|
glycolysis
() | |
|
SLC25A1
(Cell-free assay) | 3.5 μM(Kd) |
CTPI-2 is a unique regulator of glycolysis that limits the metabolic plasticity of cancer stem cells (CSCs). CTPI-2 (26 mg/kg; i.p.) inhibits tumor growth in in vivo models of non-small cell lung cancer (NSCLC).
CTPI-2 (50 mg/kg; i.p.; alternate days for 12 weeks) completely averts weight gain in the prevention study and leads to significant weight loss in the reversion study.
CTPI-2 prevents steatohepatitis and normalizes glucose tolerance. CTPI-2 lowers the levels of circulating IL-6 while increasing anti-inflammatory IL-4 and IL-10 and also reduced the monocyte chemoattractant protein-1 and monokine-induced by interferon-γ that attract neutrophils and monocytes. CTPI-2 regulates the citrate pool, the lipogenic and the gluconeogenic pathways.
| Animal Model: | C57BL/6J mice (HFD-fed mice) |
| Dosage: | 50 mg/kg |
| Administration: | Alternate days via the intraperitoneal route for 12 weeks |
| Result: | Completely averted weight gain in the prevention study and led to significant weight loss in the reversion study. |
